Intravenous Continuous LMWH Seems to be Safe Alternative to UFH in VV ECMO Patients
Study Details
Study Description
Brief Summary
Unfractionated heparin (UFH) is worldwide anticoagulation used and recommended anticoagulation in patients with ECMO support. However, it is accompanied with incidence of bleeding or thrombotic compliaction at about 40-60% and high mortality. Because ECMO produce primary haemosthasis pathology, there is a theory that prophylaxis of thrombosis with low molecular weight heparin (LMWH) e.g. Enoxaparin might be sufficient to prevent ECMO throbosis and thrombosis development in patients.
We decided to performed retrospective observation study and analysis of data, from may 2019 until august 2023, in all patients who were put on VV ECMO and to analysis incidence of bleeding, thrombotic and neurologic complications.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Unfractionated heparin (UFH) is worldwide anticoagulation used and recommended anticoagulation in patients with ECMO support. However, it is accompanied with incidence of bleeding or thrombotic compliaction at about 40-60% and high mortality. Because ECMO produce primary haemosthasis pathology, there is a theory that prophylaxis of thrombosis with low molecular weight heparin (LMWH) e.g. Enoxaparin might be sufficient to prevent ECMO throbosis and thrombosis development in patients. This phenomenon of primary haemosthasis pathology may protect ECMO from thrombotic complication as primary haemosthasis plays major role in haemosthasis taking places in high shear stress condiditon such as ECMO. Because LMWH is connected with lower incidence of bleeding complication and HIT (heparin induced thrombocytopenia) in general, in case that patients on VV ECMO developed primary haemosthasis pathology detected by PFA 200, we started to use LMWH instead of UFH in VV ECMO patients.
We decided to performed retrospective observation study and analysis of data, from may 2019 until august 2023, in all patients who were put on VV ECMO and to analysis incidence of bleeding, thrombotic and neurologic complications. We want to compare this incidence of compliactions with data known from patients with other studies using UFH.
Study Design
Outcome Measures
Primary Outcome Measures
- Incidence of major bleeding complications [Daty from may 2019 till august 2023]
Defined by ECMO registry
- Incidence of major thrombotic complications [Daty from may 2019 till august 2023]
Defined by ECMO registry
- Incidence of major neurologic complications [Daty from may 2019 till august 2023]
Defined by ECMO registry
Eligibility Criteria
Criteria
Inclusion Criteria:
-
VV ECMO - use of 2 separate cannulas (jugular and femoral)
-
anticoagulation with only intravenous continuous LMWH (Enoxaparin)
-
only a period of the first ECMO set running
Exclusion Criteria:
-
pregnancy
-
Avalon cannula (one double lumen cannula)
-
patients after thoraco-abdominal surgery
-
patients after lung transplantation in early postoperative period
-
patients after trauma without any type of heparin ,,heparin free" ECMO
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Unoversity Hospital Motol, Department of Anaesthesiology and Intensive Care | Prague | Czechia | 150 06 |
Sponsors and Collaborators
- University Hospital, Motol
Investigators
- Principal Investigator: Miroslav Durila, prof., Department of anesthesiology and intensive care medicine, Motol Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 15082023